L-isoleucine vs L-alloisoleucine: rotation, regulation and the label
L-isoleucine and L-alloisoleucine are diastereomers: the same C6H13NO2 formula, the same 131.17 g/mol, and one configuration difference at C-3. That single difference changes the rotation, the crystal and the regulatory position; it does not change the titration. Only L-isoleucine has an established supplement use, and the epimer is a reference material and a process marker rather than an alternative grade.
The two epimers differ at one carbon, overlap in rotation and titrate identically, so the specification, the chromatogram and the label have to do the work.
Two stereocentres, four isomers
Isoleucine has two stereocentres, at C-2 and at C-3, so four configurations exist. L-isoleucine is (2S,3S) and L-alloisoleucine is (2S,3R); the two D forms mirror them. The L pair shares the C-2 configuration and differs at C-3, which makes them diastereomers rather than enantiomers. Diastereomers have different physical properties, which is why the rotation, the melting point and the crystal form can separate them even though the mass cannot.
| Property | L-isoleucine | L-alloisoleucine |
|---|---|---|
| CAS number | 73-32-5 | 1509-34-8 |
| Configuration | (2S,3S)-2-amino-3-methylpentanoic acid | (2S,3R)-2-amino-3-methylpentanoic acid |
| Formula and molecular weight | C6H13NO2 · 131.17 g/mol | C6H13NO2 · 131.17 g/mol |
| Specific rotation | +38.0° to +41.0° (catalog, dried basis) | About +35° to +39° (c=4, 6 M HCl, supplier data) |
| Melting point with decomposition | About 284 °C | About 272 °C |
| Established supplement use | Yes, as an amino acid ingredient | No; reference and research use |
The epimer is not a synthetic curiosity. The C-3 centre can invert under strong acid and heat, so alloisoleucine appears as an artefact when proteins are hydrolysed in hydrochloric acid, and it occurs in a small number of natural peptides. A supplier whose route includes a hydrolysis step has a reason to watch the figure; a crystallisation route has less of one.
Rotation: close enough to overlap
The polarimeter is the first test anyone reaches for, and it is stronger on paper than in practice. The catalog window for L-isoleucine is +38.0° to +41.0° on the dried basis. L-alloisoleucine reads roughly +35° to +39° in the same acid solvent, so the two windows overlap in their upper and lower thirds.
The arithmetic shows the problem. Take a lot that is 95% L-isoleucine reading +40° and 5% alloisoleucine reading +37°: the mixture reads about +39.8°, comfortably inside the window. At 10% alloisoleucine it still reads about +39.6°. The rotation moves in the right direction, but a release limit of +38.0° does not exclude the epimer at a level that matters to a specification.
What rotation does catch is the gross failure. D-isoleucine reads negative, DL-isoleucine sits near zero, and an achiral filler such as norleucine dilutes the reading toward zero. A lot outside the window has a real problem; a lot inside it has only passed one gate.
Assay: the same number for both
The release assay in this catalog is a titration, and both epimers carry the same carboxyl group. At the same mass, they consume the same titrant, so a certificate can report 100.0% on the dried basis for either one, and for any mixture of the two. The assay is a mass-balance test, not a stereochemical one.
Chromatography without a chiral dimension does not settle it either. On a conventional reversed-phase method the pair can be poorly resolved or co-elute, and an ultraviolet detector sees very little because isoleucine has no chromophore; most methods derivative the amino acid or use a refractive-index or evaporative detector. Mass spectrometry separates by mass, and the two masses are identical. Only a method that resolves the geometry produces a number for the epimer.
The separation that produces a number
Three routes are routine. Derivatisation with a chiral reagent such as Marfey's reagent turns the mixture into derivatives that separate on a reversed-phase column; a chiral stationary phase separates the underivatised amino acids; and an amino-acid analyser with ninhydrin resolves the pair on ion exchange. All three need an alloisoleucine standard, because a peak is not identified by its position alone.
The report should give the resolution between the isoleucine and alloisoleucine peaks, the limit of quantification and the recovery from a spiked sample. A method with a limit of quantification at 0.5% cannot support a specification of ≤0.1%. Ask for the validation, not only the result, and ask which sample was tested: the retained sample from the lot is the one that counts.
Regulation and the label
The two names are not interchangeable in a file. In the EU, amino acids sit outside the Annex II positive list, so L-isoleucine falls under general food law, with the labelling rules of Regulation (EU) No 1169/2011 and the supplement particulars of Directive 2002/46/EC. L-alloisoleucine has no established food use, so it would need its own safety and market-entry position before it could appear in a supplement; a position that covers L-isoleucine does not extend to it.
In the US, an amino acid can be a dietary ingredient under DSHEA if the supplier supports the basis, and the Supplement Facts panel must name the ingredient. L-alloisoleucine does not inherit that basis. In the UK the retained rules apply. In all three markets the label test is the same: the name on the panel must be the substance in the drum, and a certificate for the epimer cannot release a lot declared as L-isoleucine.
A blend label declares the amino acids it contains, so a 2:1:1 leucine : isoleucine : valine premix has to name all three. The ratio belongs to the formula; the epimer question belongs to the isoleucine line, and the two are checked separately.
When to choose which
Choose L-isoleucine for capsules, tablets, powder sticks, beverages and blends, and for any product that will carry a food or supplement label. The material is specified at 98.5–101.5% on the dried basis with a rotation of +38.0° to +41.0°, and the certificate should add an alloisoleucine figure where the risk assessment asks for one.
Choose L-alloisoleucine only as an analytical reference standard, a spiking material for method validation, or a research reagent, and handle it with its own specification and its own documentation. It is not a substitute for isoleucine, and a quotation that offers it as one is a warning about the supplier.
If a supplier cannot say which epimer the drum contains, the question to ask is about the chromatogram. The identity page sets out the four-layer proof; the release tests are on the COA page, the grade portfolio on the grade page, and the market position on the compliance page. The product hub carries the catalog specification, and assay is defined in the glossary.
Related documents
Send the specification you intend to use — grade, quantity and destination market — and we will reply with the batch COA, the technical data sheet and a quotation.
Request a quotation